Revvity’s Q2 2026 earnings call drew CEO Prahlad R. Singh, CFO Maxwell Krakowiak, IR head Stephen Barr Willoughby, analysts.
Raised 2026 pro forma organic growth outlook to 4%-5%; pro forma revenue seen at USD 2.83 billion-USD 2.86 billion.
Lifted pro forma adjusted EPS view to USD 5.30-USD 5.40; pro forma adjusted operating margin target moved to 28.7%.
Q2 revenue USD 711 million; pro forma organic growth 3%; adjusted EPS USD 1.41, helped by USD 16 million tariff refunds.
Signed definitive agreement to divest China immunodiagnostics business; closing expected by end-2027; management cited rising AI-driven instrument demand and backlog.
RVTY•
